Page 25 - Wondergem

References 1 1. Montoto S and Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29:1827-1834
2. Relander T, Johnson N, Farinha P et al. Prognostic factors in follicular lymphoma. J Clin Oncol 2010;28:2902- 2913
3. Montoto S, Lopez Guillermo A, Altes A et al. Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma in first progression. Annals Onc 2004;15:1484-1498
4. Al-tourah AJ, Gill KK, Chhanabhai M et al. Population based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008:26(32):3272-3278
5. Link BK, Maurer MJ, Nowakowski GS et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272-3278
6. Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587-1594
7. Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17)2426-2433
8. Conconi A, Ponzio C, Lobetti-Bodoni C et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157(2):188-196
9. Giné E, Montoto S, Bosch F et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17(10):1539-1545
10. Garvin AJ, Simon RM, Osborne CK et al. An autopsy study of histologic progression in non-Hodgkin’s lymphomas. 192 cases from the National Cancer Institute. Cancer 1983;52(3):393-398
11. Wagner-Johnston ND, Link BK, Byrtek M et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS) Blood 2015 prepub. June 23
12. Ardeshna KM, Qian W, Smith P et al. Rituximab versus a watch and wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomized phase 3 trial. Lancet Oncol. 2014:15(4):424-435
13. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169
14. FarinhaP,MasoudiH,SkinniderBFetal.Analysisofmultiplebiomarkersshowsthatlymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL. Blood 2005;106(6): 2169-2174
15. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patietns with follicular lymphoma enrolled onto the GELA-GOELAMS FL- 2000 trial. J Clin Oncol 2008;26(3):440-446
16. De Jong D, Koster A, Hagenbeek A. Impact of the tumor microenvironment on prognosis in FL is dependent on specific treatment protocols. Haematologica 2009;94:70-77
17. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25: 390-398
18. Farinha P, Kyle AH, Minchinton AI et al. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010;95(12):2157-2160
19. Farinha P, Al-Tourah A, Gill K et al. The architectural pattern of FOXp3-positive T cells in folicular lymphoma is an independent predictor of survival and histologic transformation Blood 2010;115(2):289-295
20. Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995;13(7):1726-1733
21. Boellaard R, O’Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Molec Imaging. 2010;37:181-200.
22. Lin C, Itti E, Haioun C et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J nucl med 2007 ;48(10):1626-1632
23. Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leuk lymphoma 2009;50(11):1748-1749
Introduction and scope of this thesis
23